Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19632286 | 1.00 | HDAC1 (0.38) | HDAC1GPR119MAP4K4TSHRNTRK1 | |
| SCHEMBL21058315 | 0.85 | GPR119 (0.38) | HDAC1GPR119MAP4K4ELANESETD7 | |
| SCHEMBL19632326 | 0.85 | GPR119 (0.38) | HDAC1GPR119MAP4K4ELANESETD7 | |
| SCHEMBL21260292 | 0.84 | GPR119 (0.37) | HDAC1GPR119MAP4K4ELANESETD7 | |
| SCHEMBL21260335 | 0.84 | HDAC1 (0.34) | HDAC1GPR119MAP4K4TSHRNTRK1 | |
| SCHEMBL28713999 | 0.84 | HDAC1 (0.34) | HDAC1GPR119MAP4K4TSHRNTRK1 | |
| SCHEMBL22018067 | 0.83 | DRD3 (0.42) | HDAC1GPR119MAP4K4TSHRELANE | |
| SCHEMBL19632319 | 0.83 | GPR119 (0.37) | HDAC1GPR119MAP4K4ELANESETD7 | |
| SCHEMBL22615358 | 0.83 | MEN1 (0.39) | HDAC1GPR119MAP4K4ELANESETD7 | |
| SCHEMBL17925539 | 0.83 | HDAC1 (0.39) | HDAC1GPR119MAP4K4ELANESETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458455-B1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN, SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-10604527-B2 | Pyrazine compounds for the treatment of hepatitis B infection | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190185476-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185476-A1 | NOVEL PYRAZINE COMPOUNDS WITH OXYGEN SULFUR AND NITROGEN LINKER FOR THE TREATMENT OF INFECTIOUS DISEASES | SQOR, HCCS, CBR1 | HDAC1 1400/4885GPR119 1604/4885MAP4K4 1588/4885 |
| US-10604527-B2 | Pyrazine compounds for the treatment of hepatitis B infection | HAVCR2, CYP3A43, CYP3A5 | HDAC1 367/4885GPR119 917/4885MAP4K4 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.